nodes	percent_of_prediction	percent_of_DWPC	metapath
Mirtazapine—HTR3A—vagus nerve—esophageal cancer	0.0262	0.184	CbGeAlD
Mirtazapine—HTR7—vagus nerve—esophageal cancer	0.0169	0.119	CbGeAlD
Mirtazapine—HTR2A—vagus nerve—esophageal cancer	0.0106	0.0741	CbGeAlD
Mirtazapine—HRH3—digestive system—esophageal cancer	0.0062	0.0435	CbGeAlD
Mirtazapine—HTR7—neck—esophageal cancer	0.00371	0.0261	CbGeAlD
Mirtazapine—ADRB1—bronchus—esophageal cancer	0.00303	0.0213	CbGeAlD
Mirtazapine—HTR3A—digestive system—esophageal cancer	0.00297	0.0208	CbGeAlD
Mirtazapine—HTR2B—smooth muscle tissue—esophageal cancer	0.00284	0.0199	CbGeAlD
Mirtazapine—HTR7—epithelium—esophageal cancer	0.00253	0.0177	CbGeAlD
Mirtazapine—HTR3A—lung—esophageal cancer	0.00248	0.0174	CbGeAlD
Mirtazapine—ADRA1A—epithelium—esophageal cancer	0.00244	0.0171	CbGeAlD
Mirtazapine—HTR7—smooth muscle tissue—esophageal cancer	0.00243	0.0171	CbGeAlD
Mirtazapine—HTR2A—neck—esophageal cancer	0.00232	0.0162	CbGeAlD
Mirtazapine—ADRA2C—bronchus—esophageal cancer	0.00229	0.016	CbGeAlD
Mirtazapine—SLC6A4—digestive system—esophageal cancer	0.00226	0.0159	CbGeAlD
Mirtazapine—HTR2B—digestive system—esophageal cancer	0.00224	0.0157	CbGeAlD
Mirtazapine—HTR7—trachea—esophageal cancer	0.00223	0.0157	CbGeAlD
Mirtazapine—SLC6A3—lung—esophageal cancer	0.00206	0.0145	CbGeAlD
Mirtazapine—ADRA2C—trachea—esophageal cancer	0.00205	0.0144	CbGeAlD
Mirtazapine—ADRB1—lung—esophageal cancer	0.00196	0.0137	CbGeAlD
Mirtazapine—HTR7—digestive system—esophageal cancer	0.00192	0.0135	CbGeAlD
Mirtazapine—SLC6A4—lung—esophageal cancer	0.00189	0.0133	CbGeAlD
Mirtazapine—HRH1—epithelium—esophageal cancer	0.00189	0.0132	CbGeAlD
Mirtazapine—HTR2B—lung—esophageal cancer	0.00187	0.0132	CbGeAlD
Mirtazapine—ADRA2A—bronchus—esophageal cancer	0.00182	0.0128	CbGeAlD
Mirtazapine—HRH1—smooth muscle tissue—esophageal cancer	0.00182	0.0128	CbGeAlD
Mirtazapine—HRH1—trachea—esophageal cancer	0.00167	0.0117	CbGeAlD
Mirtazapine—SLC6A2—lung—esophageal cancer	0.00167	0.0117	CbGeAlD
Mirtazapine—ADRA2A—trachea—esophageal cancer	0.00164	0.0115	CbGeAlD
Mirtazapine—HTR7—lung—esophageal cancer	0.00161	0.0113	CbGeAlD
Mirtazapine—HTR2A—epithelium—esophageal cancer	0.00158	0.0111	CbGeAlD
Mirtazapine—CYP1A2—digestive system—esophageal cancer	0.00153	0.0108	CbGeAlD
Mirtazapine—HTR2A—smooth muscle tissue—esophageal cancer	0.00152	0.0107	CbGeAlD
Mirtazapine—DRD2—lung—esophageal cancer	0.00152	0.0106	CbGeAlD
Mirtazapine—ADRA2C—lung—esophageal cancer	0.00148	0.0104	CbGeAlD
Mirtazapine—CYP2C9—digestive system—esophageal cancer	0.00145	0.0102	CbGeAlD
Mirtazapine—HRH1—digestive system—esophageal cancer	0.00143	0.0101	CbGeAlD
Mirtazapine—HTR2A—trachea—esophageal cancer	0.00139	0.00977	CbGeAlD
Mirtazapine—HTR2B—lymph node—esophageal cancer	0.00128	0.009	CbGeAlD
Mirtazapine—CYP1A2—lung—esophageal cancer	0.00128	0.00898	CbGeAlD
Mirtazapine—HTR2A—digestive system—esophageal cancer	0.0012	0.00841	CbGeAlD
Mirtazapine—HRH1—lung—esophageal cancer	0.0012	0.00841	CbGeAlD
Mirtazapine—Face oedema—Capecitabine—esophageal cancer	0.00119	0.00248	CcSEcCtD
Mirtazapine—Aplastic anaemia—Methotrexate—esophageal cancer	0.00118	0.00248	CcSEcCtD
Mirtazapine—ADRA2A—lung—esophageal cancer	0.00118	0.00826	CbGeAlD
Mirtazapine—Bradycardia—Cisplatin—esophageal cancer	0.00117	0.00246	CcSEcCtD
Mirtazapine—Urinary retention—Capecitabine—esophageal cancer	0.00117	0.00244	CcSEcCtD
Mirtazapine—Mood swings—Capecitabine—esophageal cancer	0.00116	0.00244	CcSEcCtD
Mirtazapine—Ataxia—Capecitabine—esophageal cancer	0.00115	0.00242	CcSEcCtD
Mirtazapine—Coma—Methotrexate—esophageal cancer	0.00115	0.00241	CcSEcCtD
Mirtazapine—Dehydration—Capecitabine—esophageal cancer	0.00114	0.00239	CcSEcCtD
Mirtazapine—SLC6A2—lymph node—esophageal cancer	0.00114	0.00799	CbGeAlD
Mirtazapine—Mouth ulceration—Methotrexate—esophageal cancer	0.00114	0.00238	CcSEcCtD
Mirtazapine—Urine output increased—Methotrexate—esophageal cancer	0.00114	0.00238	CcSEcCtD
Mirtazapine—Bladder pain—Methotrexate—esophageal cancer	0.00114	0.00238	CcSEcCtD
Mirtazapine—Urinary tract disorder—Cisplatin—esophageal cancer	0.00114	0.00238	CcSEcCtD
Mirtazapine—Liver function test abnormal—Capecitabine—esophageal cancer	0.00113	0.00237	CcSEcCtD
Mirtazapine—Urethral disorder—Cisplatin—esophageal cancer	0.00113	0.00237	CcSEcCtD
Mirtazapine—Dry skin—Capecitabine—esophageal cancer	0.00113	0.00236	CcSEcCtD
Mirtazapine—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00112	0.00235	CcSEcCtD
Mirtazapine—Pulmonary oedema—Methotrexate—esophageal cancer	0.00112	0.00235	CcSEcCtD
Mirtazapine—CYP3A4—digestive system—esophageal cancer	0.00111	0.00779	CbGeAlD
Mirtazapine—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00111	0.00231	CcSEcCtD
Mirtazapine—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.00111	0.00231	CcSEcCtD
Mirtazapine—CYP2D6—digestive system—esophageal cancer	0.00109	0.00766	CbGeAlD
Mirtazapine—Gastritis—Capecitabine—esophageal cancer	0.00109	0.00228	CcSEcCtD
Mirtazapine—Muscular weakness—Capecitabine—esophageal cancer	0.00108	0.00227	CcSEcCtD
Mirtazapine—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00108	0.00227	CcSEcCtD
Mirtazapine—Eye disorder—Cisplatin—esophageal cancer	0.00108	0.00225	CcSEcCtD
Mirtazapine—Tinnitus—Cisplatin—esophageal cancer	0.00107	0.00225	CcSEcCtD
Mirtazapine—Lymphadenopathy—Methotrexate—esophageal cancer	0.00107	0.00224	CcSEcCtD
Mirtazapine—Cardiac disorder—Cisplatin—esophageal cancer	0.00107	0.00224	CcSEcCtD
Mirtazapine—Abdominal distension—Capecitabine—esophageal cancer	0.00107	0.00224	CcSEcCtD
Mirtazapine—Influenza—Capecitabine—esophageal cancer	0.00106	0.00222	CcSEcCtD
Mirtazapine—Asthma—Capecitabine—esophageal cancer	0.00106	0.00222	CcSEcCtD
Mirtazapine—Diabetes mellitus—Methotrexate—esophageal cancer	0.00105	0.0022	CcSEcCtD
Mirtazapine—Polyuria—Methotrexate—esophageal cancer	0.00104	0.00218	CcSEcCtD
Mirtazapine—Angina pectoris—Capecitabine—esophageal cancer	0.00103	0.00216	CcSEcCtD
Mirtazapine—Sweating increased—Capecitabine—esophageal cancer	0.00103	0.00216	CcSEcCtD
Mirtazapine—Arrhythmia—Cisplatin—esophageal cancer	0.00103	0.00216	CcSEcCtD
Mirtazapine—Bronchitis—Capecitabine—esophageal cancer	0.00102	0.00214	CcSEcCtD
Mirtazapine—Alopecia—Cisplatin—esophageal cancer	0.00102	0.00213	CcSEcCtD
Mirtazapine—ADRA2C—lymph node—esophageal cancer	0.00101	0.00708	CbGeAlD
Mirtazapine—Pancytopenia—Capecitabine—esophageal cancer	0.00101	0.00211	CcSEcCtD
Mirtazapine—Malnutrition—Cisplatin—esophageal cancer	0.001	0.0021	CcSEcCtD
Mirtazapine—HTR2A—lung—esophageal cancer	0.001	0.00702	CbGeAlD
Mirtazapine—Dysuria—Capecitabine—esophageal cancer	0.000992	0.00208	CcSEcCtD
Mirtazapine—Neutropenia—Capecitabine—esophageal cancer	0.000992	0.00208	CcSEcCtD
Mirtazapine—Flatulence—Cisplatin—esophageal cancer	0.000988	0.00207	CcSEcCtD
Mirtazapine—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000969	0.00203	CcSEcCtD
Mirtazapine—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000969	0.00203	CcSEcCtD
Mirtazapine—Weight increased—Capecitabine—esophageal cancer	0.000966	0.00202	CcSEcCtD
Mirtazapine—Weight decreased—Capecitabine—esophageal cancer	0.00096	0.00201	CcSEcCtD
Mirtazapine—Pneumonia—Capecitabine—esophageal cancer	0.000952	0.00199	CcSEcCtD
Mirtazapine—Tremor—Cisplatin—esophageal cancer	0.00094	0.00197	CcSEcCtD
Mirtazapine—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000938	0.00196	CcSEcCtD
Mirtazapine—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000933	0.00195	CcSEcCtD
Mirtazapine—Lethargy—Methotrexate—esophageal cancer	0.000933	0.00195	CcSEcCtD
Mirtazapine—Ill-defined disorder—Cisplatin—esophageal cancer	0.000931	0.00195	CcSEcCtD
Mirtazapine—Myocardial infarction—Capecitabine—esophageal cancer	0.000927	0.00194	CcSEcCtD
Mirtazapine—Anaemia—Cisplatin—esophageal cancer	0.000927	0.00194	CcSEcCtD
Mirtazapine—Jaundice—Capecitabine—esophageal cancer	0.000922	0.00193	CcSEcCtD
Mirtazapine—Stomatitis—Capecitabine—esophageal cancer	0.000922	0.00193	CcSEcCtD
Mirtazapine—Urinary tract infection—Capecitabine—esophageal cancer	0.00092	0.00193	CcSEcCtD
Mirtazapine—Conjunctivitis—Capecitabine—esophageal cancer	0.00092	0.00193	CcSEcCtD
Mirtazapine—Osteoarthritis—Methotrexate—esophageal cancer	0.000914	0.00191	CcSEcCtD
Mirtazapine—Malaise—Cisplatin—esophageal cancer	0.000905	0.00189	CcSEcCtD
Mirtazapine—Haematuria—Capecitabine—esophageal cancer	0.000902	0.00189	CcSEcCtD
Mirtazapine—Leukopenia—Cisplatin—esophageal cancer	0.000898	0.00188	CcSEcCtD
Mirtazapine—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000895	0.00187	CcSEcCtD
Mirtazapine—Epistaxis—Capecitabine—esophageal cancer	0.000892	0.00187	CcSEcCtD
Mirtazapine—Agranulocytosis—Capecitabine—esophageal cancer	0.000883	0.00185	CcSEcCtD
Mirtazapine—Convulsion—Cisplatin—esophageal cancer	0.000869	0.00182	CcSEcCtD
Mirtazapine—Mood swings—Methotrexate—esophageal cancer	0.000866	0.00181	CcSEcCtD
Mirtazapine—Bradycardia—Capecitabine—esophageal cancer	0.000865	0.00181	CcSEcCtD
Mirtazapine—Ataxia—Methotrexate—esophageal cancer	0.000859	0.0018	CcSEcCtD
Mirtazapine—Myalgia—Cisplatin—esophageal cancer	0.000854	0.00179	CcSEcCtD
Mirtazapine—Rhinitis—Capecitabine—esophageal cancer	0.000852	0.00178	CcSEcCtD
Mirtazapine—Anxiety—Cisplatin—esophageal cancer	0.000851	0.00178	CcSEcCtD
Mirtazapine—Hepatitis—Capecitabine—esophageal cancer	0.000849	0.00178	CcSEcCtD
Mirtazapine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000848	0.00178	CcSEcCtD
Mirtazapine—Hypoaesthesia—Capecitabine—esophageal cancer	0.000845	0.00177	CcSEcCtD
Mirtazapine—Liver function test abnormal—Methotrexate—esophageal cancer	0.000844	0.00177	CcSEcCtD
Mirtazapine—Discomfort—Cisplatin—esophageal cancer	0.000844	0.00177	CcSEcCtD
Mirtazapine—Pharyngitis—Capecitabine—esophageal cancer	0.000843	0.00177	CcSEcCtD
Mirtazapine—Urinary tract disorder—Capecitabine—esophageal cancer	0.000839	0.00176	CcSEcCtD
Mirtazapine—Oedema peripheral—Capecitabine—esophageal cancer	0.000837	0.00175	CcSEcCtD
Mirtazapine—Urethral disorder—Capecitabine—esophageal cancer	0.000833	0.00174	CcSEcCtD
Mirtazapine—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000823	0.00172	CcSEcCtD
Mirtazapine—HRH1—lymph node—esophageal cancer	0.00082	0.00575	CbGeAlD
Mirtazapine—Oedema—Cisplatin—esophageal cancer	0.000819	0.00171	CcSEcCtD
Mirtazapine—Infection—Cisplatin—esophageal cancer	0.000813	0.0017	CcSEcCtD
Mirtazapine—ADRA2A—lymph node—esophageal cancer	0.000805	0.00565	CbGeAlD
Mirtazapine—Erythema multiforme—Capecitabine—esophageal cancer	0.000803	0.00168	CcSEcCtD
Mirtazapine—Nervous system disorder—Cisplatin—esophageal cancer	0.000803	0.00168	CcSEcCtD
Mirtazapine—Thrombocytopenia—Cisplatin—esophageal cancer	0.000802	0.00168	CcSEcCtD
Mirtazapine—Tachycardia—Cisplatin—esophageal cancer	0.000799	0.00167	CcSEcCtD
Mirtazapine—Skin disorder—Cisplatin—esophageal cancer	0.000795	0.00166	CcSEcCtD
Mirtazapine—Eye disorder—Capecitabine—esophageal cancer	0.000794	0.00166	CcSEcCtD
Mirtazapine—Tinnitus—Capecitabine—esophageal cancer	0.000792	0.00166	CcSEcCtD
Mirtazapine—Hyperhidrosis—Cisplatin—esophageal cancer	0.000791	0.00166	CcSEcCtD
Mirtazapine—Asthma—Methotrexate—esophageal cancer	0.00079	0.00165	CcSEcCtD
Mirtazapine—Cardiac disorder—Capecitabine—esophageal cancer	0.000788	0.00165	CcSEcCtD
Mirtazapine—Eosinophilia—Methotrexate—esophageal cancer	0.000782	0.00164	CcSEcCtD
Mirtazapine—Anorexia—Cisplatin—esophageal cancer	0.00078	0.00163	CcSEcCtD
Mirtazapine—Pancreatitis—Methotrexate—esophageal cancer	0.000774	0.00162	CcSEcCtD
Mirtazapine—Angiopathy—Capecitabine—esophageal cancer	0.000771	0.00161	CcSEcCtD
Mirtazapine—Hypotension—Cisplatin—esophageal cancer	0.000765	0.0016	CcSEcCtD
Mirtazapine—Chills—Capecitabine—esophageal cancer	0.000762	0.0016	CcSEcCtD
Mirtazapine—Arrhythmia—Capecitabine—esophageal cancer	0.000759	0.00159	CcSEcCtD
Mirtazapine—Alopecia—Capecitabine—esophageal cancer	0.000751	0.00157	CcSEcCtD
Mirtazapine—Pancytopenia—Methotrexate—esophageal cancer	0.00075	0.00157	CcSEcCtD
Mirtazapine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000746	0.00156	CcSEcCtD
Mirtazapine—Mental disorder—Capecitabine—esophageal cancer	0.000744	0.00156	CcSEcCtD
Mirtazapine—Malnutrition—Capecitabine—esophageal cancer	0.000739	0.00155	CcSEcCtD
Mirtazapine—Dysuria—Methotrexate—esophageal cancer	0.000739	0.00155	CcSEcCtD
Mirtazapine—Neutropenia—Methotrexate—esophageal cancer	0.000739	0.00155	CcSEcCtD
Mirtazapine—Paraesthesia—Cisplatin—esophageal cancer	0.000735	0.00154	CcSEcCtD
Mirtazapine—Dyspnoea—Cisplatin—esophageal cancer	0.00073	0.00153	CcSEcCtD
Mirtazapine—Flatulence—Capecitabine—esophageal cancer	0.000729	0.00153	CcSEcCtD
Mirtazapine—Erectile dysfunction—Methotrexate—esophageal cancer	0.000728	0.00152	CcSEcCtD
Mirtazapine—Dysgeusia—Capecitabine—esophageal cancer	0.000724	0.00152	CcSEcCtD
Mirtazapine—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000721	0.00151	CcSEcCtD
Mirtazapine—Back pain—Capecitabine—esophageal cancer	0.000715	0.0015	CcSEcCtD
Mirtazapine—Decreased appetite—Cisplatin—esophageal cancer	0.000712	0.00149	CcSEcCtD
Mirtazapine—Pneumonia—Methotrexate—esophageal cancer	0.000708	0.00148	CcSEcCtD
Mirtazapine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000707	0.00148	CcSEcCtD
Mirtazapine—Drowsiness—Methotrexate—esophageal cancer	0.000704	0.00147	CcSEcCtD
Mirtazapine—Pain—Cisplatin—esophageal cancer	0.0007	0.00147	CcSEcCtD
Mirtazapine—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000698	0.00146	CcSEcCtD
Mirtazapine—Tremor—Capecitabine—esophageal cancer	0.000693	0.00145	CcSEcCtD
Mirtazapine—Stomatitis—Methotrexate—esophageal cancer	0.000687	0.00144	CcSEcCtD
Mirtazapine—Ill-defined disorder—Capecitabine—esophageal cancer	0.000686	0.00144	CcSEcCtD
Mirtazapine—Conjunctivitis—Methotrexate—esophageal cancer	0.000685	0.00143	CcSEcCtD
Mirtazapine—Anaemia—Capecitabine—esophageal cancer	0.000683	0.00143	CcSEcCtD
Mirtazapine—Sweating—Methotrexate—esophageal cancer	0.000675	0.00141	CcSEcCtD
Mirtazapine—Feeling abnormal—Cisplatin—esophageal cancer	0.000675	0.00141	CcSEcCtD
Mirtazapine—Haematuria—Methotrexate—esophageal cancer	0.000672	0.00141	CcSEcCtD
Mirtazapine—Malaise—Capecitabine—esophageal cancer	0.000667	0.0014	CcSEcCtD
Mirtazapine—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000666	0.00139	CcSEcCtD
Mirtazapine—Epistaxis—Methotrexate—esophageal cancer	0.000664	0.00139	CcSEcCtD
Mirtazapine—Vertigo—Capecitabine—esophageal cancer	0.000664	0.00139	CcSEcCtD
Mirtazapine—Syncope—Capecitabine—esophageal cancer	0.000663	0.00139	CcSEcCtD
Mirtazapine—Leukopenia—Capecitabine—esophageal cancer	0.000662	0.00139	CcSEcCtD
Mirtazapine—Agranulocytosis—Methotrexate—esophageal cancer	0.000657	0.00138	CcSEcCtD
Mirtazapine—Palpitations—Capecitabine—esophageal cancer	0.000653	0.00137	CcSEcCtD
Mirtazapine—Loss of consciousness—Capecitabine—esophageal cancer	0.00065	0.00136	CcSEcCtD
Mirtazapine—Body temperature increased—Cisplatin—esophageal cancer	0.000647	0.00136	CcSEcCtD
Mirtazapine—Cough—Capecitabine—esophageal cancer	0.000645	0.00135	CcSEcCtD
Mirtazapine—Hypertension—Capecitabine—esophageal cancer	0.000638	0.00134	CcSEcCtD
Mirtazapine—Hepatitis—Methotrexate—esophageal cancer	0.000632	0.00132	CcSEcCtD
Mirtazapine—Arthralgia—Capecitabine—esophageal cancer	0.000629	0.00132	CcSEcCtD
Mirtazapine—Chest pain—Capecitabine—esophageal cancer	0.000629	0.00132	CcSEcCtD
Mirtazapine—Myalgia—Capecitabine—esophageal cancer	0.000629	0.00132	CcSEcCtD
Mirtazapine—Pharyngitis—Methotrexate—esophageal cancer	0.000628	0.00131	CcSEcCtD
Mirtazapine—Anxiety—Capecitabine—esophageal cancer	0.000627	0.00131	CcSEcCtD
Mirtazapine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000625	0.00131	CcSEcCtD
Mirtazapine—Urinary tract disorder—Methotrexate—esophageal cancer	0.000624	0.00131	CcSEcCtD
Mirtazapine—Discomfort—Capecitabine—esophageal cancer	0.000622	0.0013	CcSEcCtD
Mirtazapine—Urethral disorder—Methotrexate—esophageal cancer	0.00062	0.0013	CcSEcCtD
Mirtazapine—Dry mouth—Capecitabine—esophageal cancer	0.000616	0.00129	CcSEcCtD
Mirtazapine—Confusional state—Capecitabine—esophageal cancer	0.000608	0.00127	CcSEcCtD
Mirtazapine—Oedema—Capecitabine—esophageal cancer	0.000603	0.00126	CcSEcCtD
Mirtazapine—Hypersensitivity—Cisplatin—esophageal cancer	0.000603	0.00126	CcSEcCtD
Mirtazapine—Infection—Capecitabine—esophageal cancer	0.000599	0.00126	CcSEcCtD
Mirtazapine—Erythema multiforme—Methotrexate—esophageal cancer	0.000598	0.00125	CcSEcCtD
Mirtazapine—Shock—Capecitabine—esophageal cancer	0.000594	0.00124	CcSEcCtD
Mirtazapine—Nervous system disorder—Capecitabine—esophageal cancer	0.000592	0.00124	CcSEcCtD
Mirtazapine—Eye disorder—Methotrexate—esophageal cancer	0.000591	0.00124	CcSEcCtD
Mirtazapine—Thrombocytopenia—Capecitabine—esophageal cancer	0.000591	0.00124	CcSEcCtD
Mirtazapine—Tinnitus—Methotrexate—esophageal cancer	0.00059	0.00123	CcSEcCtD
Mirtazapine—Tachycardia—Capecitabine—esophageal cancer	0.000589	0.00123	CcSEcCtD
Mirtazapine—Asthenia—Cisplatin—esophageal cancer	0.000587	0.00123	CcSEcCtD
Mirtazapine—Cardiac disorder—Methotrexate—esophageal cancer	0.000587	0.00123	CcSEcCtD
Mirtazapine—Skin disorder—Capecitabine—esophageal cancer	0.000586	0.00123	CcSEcCtD
Mirtazapine—Hyperhidrosis—Capecitabine—esophageal cancer	0.000583	0.00122	CcSEcCtD
Mirtazapine—Anorexia—Capecitabine—esophageal cancer	0.000575	0.0012	CcSEcCtD
Mirtazapine—Angiopathy—Methotrexate—esophageal cancer	0.000574	0.0012	CcSEcCtD
Mirtazapine—Chills—Methotrexate—esophageal cancer	0.000567	0.00119	CcSEcCtD
Mirtazapine—Hypotension—Capecitabine—esophageal cancer	0.000564	0.00118	CcSEcCtD
Mirtazapine—Diarrhoea—Cisplatin—esophageal cancer	0.00056	0.00117	CcSEcCtD
Mirtazapine—Alopecia—Methotrexate—esophageal cancer	0.000559	0.00117	CcSEcCtD
Mirtazapine—Mental disorder—Methotrexate—esophageal cancer	0.000554	0.00116	CcSEcCtD
Mirtazapine—Malnutrition—Methotrexate—esophageal cancer	0.00055	0.00115	CcSEcCtD
Mirtazapine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00055	0.00115	CcSEcCtD
Mirtazapine—Insomnia—Capecitabine—esophageal cancer	0.000546	0.00114	CcSEcCtD
Mirtazapine—Paraesthesia—Capecitabine—esophageal cancer	0.000542	0.00113	CcSEcCtD
Mirtazapine—Dysgeusia—Methotrexate—esophageal cancer	0.000539	0.00113	CcSEcCtD
Mirtazapine—Dyspnoea—Capecitabine—esophageal cancer	0.000538	0.00113	CcSEcCtD
Mirtazapine—Back pain—Methotrexate—esophageal cancer	0.000532	0.00111	CcSEcCtD
Mirtazapine—Dyspepsia—Capecitabine—esophageal cancer	0.000531	0.00111	CcSEcCtD
Mirtazapine—Decreased appetite—Capecitabine—esophageal cancer	0.000525	0.0011	CcSEcCtD
Mirtazapine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000521	0.00109	CcSEcCtD
Mirtazapine—Vomiting—Cisplatin—esophageal cancer	0.00052	0.00109	CcSEcCtD
Mirtazapine—Fatigue—Capecitabine—esophageal cancer	0.00052	0.00109	CcSEcCtD
Mirtazapine—Rash—Cisplatin—esophageal cancer	0.000516	0.00108	CcSEcCtD
Mirtazapine—Pain—Capecitabine—esophageal cancer	0.000516	0.00108	CcSEcCtD
Mirtazapine—Constipation—Capecitabine—esophageal cancer	0.000516	0.00108	CcSEcCtD
Mirtazapine—Dermatitis—Cisplatin—esophageal cancer	0.000516	0.00108	CcSEcCtD
Mirtazapine—Ill-defined disorder—Methotrexate—esophageal cancer	0.000511	0.00107	CcSEcCtD
Mirtazapine—Anaemia—Methotrexate—esophageal cancer	0.000509	0.00107	CcSEcCtD
Mirtazapine—Feeling abnormal—Capecitabine—esophageal cancer	0.000497	0.00104	CcSEcCtD
Mirtazapine—Malaise—Methotrexate—esophageal cancer	0.000496	0.00104	CcSEcCtD
Mirtazapine—Vertigo—Methotrexate—esophageal cancer	0.000495	0.00104	CcSEcCtD
Mirtazapine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000493	0.00103	CcSEcCtD
Mirtazapine—Leukopenia—Methotrexate—esophageal cancer	0.000493	0.00103	CcSEcCtD
Mirtazapine—Nausea—Cisplatin—esophageal cancer	0.000486	0.00102	CcSEcCtD
Mirtazapine—Cough—Methotrexate—esophageal cancer	0.00048	0.00101	CcSEcCtD
Mirtazapine—Urticaria—Capecitabine—esophageal cancer	0.000479	0.001	CcSEcCtD
Mirtazapine—Abdominal pain—Capecitabine—esophageal cancer	0.000477	0.000999	CcSEcCtD
Mirtazapine—Body temperature increased—Capecitabine—esophageal cancer	0.000477	0.000999	CcSEcCtD
Mirtazapine—Convulsion—Methotrexate—esophageal cancer	0.000477	0.000999	CcSEcCtD
Mirtazapine—Chest pain—Methotrexate—esophageal cancer	0.000469	0.000981	CcSEcCtD
Mirtazapine—Arthralgia—Methotrexate—esophageal cancer	0.000469	0.000981	CcSEcCtD
Mirtazapine—Myalgia—Methotrexate—esophageal cancer	0.000469	0.000981	CcSEcCtD
Mirtazapine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000465	0.000974	CcSEcCtD
Mirtazapine—Discomfort—Methotrexate—esophageal cancer	0.000463	0.000969	CcSEcCtD
Mirtazapine—Confusional state—Methotrexate—esophageal cancer	0.000453	0.000948	CcSEcCtD
Mirtazapine—Infection—Methotrexate—esophageal cancer	0.000446	0.000934	CcSEcCtD
Mirtazapine—Hypersensitivity—Capecitabine—esophageal cancer	0.000445	0.000931	CcSEcCtD
Mirtazapine—Nervous system disorder—Methotrexate—esophageal cancer	0.000441	0.000922	CcSEcCtD
Mirtazapine—Thrombocytopenia—Methotrexate—esophageal cancer	0.00044	0.000921	CcSEcCtD
Mirtazapine—Skin disorder—Methotrexate—esophageal cancer	0.000436	0.000914	CcSEcCtD
Mirtazapine—Hyperhidrosis—Methotrexate—esophageal cancer	0.000434	0.000909	CcSEcCtD
Mirtazapine—Asthenia—Capecitabine—esophageal cancer	0.000433	0.000907	CcSEcCtD
Mirtazapine—Anorexia—Methotrexate—esophageal cancer	0.000428	0.000897	CcSEcCtD
Mirtazapine—Pruritus—Capecitabine—esophageal cancer	0.000427	0.000894	CcSEcCtD
Mirtazapine—Hypotension—Methotrexate—esophageal cancer	0.00042	0.000879	CcSEcCtD
Mirtazapine—Diarrhoea—Capecitabine—esophageal cancer	0.000413	0.000865	CcSEcCtD
Mirtazapine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000409	0.000857	CcSEcCtD
Mirtazapine—Insomnia—Methotrexate—esophageal cancer	0.000406	0.000851	CcSEcCtD
Mirtazapine—Paraesthesia—Methotrexate—esophageal cancer	0.000403	0.000845	CcSEcCtD
Mirtazapine—Dyspnoea—Methotrexate—esophageal cancer	0.0004	0.000839	CcSEcCtD
Mirtazapine—Somnolence—Methotrexate—esophageal cancer	0.000399	0.000836	CcSEcCtD
Mirtazapine—Dizziness—Capecitabine—esophageal cancer	0.000399	0.000836	CcSEcCtD
Mirtazapine—Dyspepsia—Methotrexate—esophageal cancer	0.000395	0.000828	CcSEcCtD
Mirtazapine—Decreased appetite—Methotrexate—esophageal cancer	0.000391	0.000818	CcSEcCtD
Mirtazapine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000388	0.000812	CcSEcCtD
Mirtazapine—Fatigue—Methotrexate—esophageal cancer	0.000387	0.000811	CcSEcCtD
Mirtazapine—Pain—Methotrexate—esophageal cancer	0.000384	0.000804	CcSEcCtD
Mirtazapine—Vomiting—Capecitabine—esophageal cancer	0.000384	0.000803	CcSEcCtD
Mirtazapine—Rash—Capecitabine—esophageal cancer	0.00038	0.000797	CcSEcCtD
Mirtazapine—Dermatitis—Capecitabine—esophageal cancer	0.00038	0.000796	CcSEcCtD
Mirtazapine—Headache—Capecitabine—esophageal cancer	0.000378	0.000792	CcSEcCtD
Mirtazapine—Feeling abnormal—Methotrexate—esophageal cancer	0.00037	0.000775	CcSEcCtD
Mirtazapine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000367	0.000769	CcSEcCtD
Mirtazapine—Nausea—Capecitabine—esophageal cancer	0.000358	0.000751	CcSEcCtD
Mirtazapine—Urticaria—Methotrexate—esophageal cancer	0.000357	0.000747	CcSEcCtD
Mirtazapine—Abdominal pain—Methotrexate—esophageal cancer	0.000355	0.000744	CcSEcCtD
Mirtazapine—Body temperature increased—Methotrexate—esophageal cancer	0.000355	0.000744	CcSEcCtD
Mirtazapine—Hypersensitivity—Methotrexate—esophageal cancer	0.000331	0.000693	CcSEcCtD
Mirtazapine—Asthenia—Methotrexate—esophageal cancer	0.000322	0.000675	CcSEcCtD
Mirtazapine—Pruritus—Methotrexate—esophageal cancer	0.000318	0.000665	CcSEcCtD
Mirtazapine—Diarrhoea—Methotrexate—esophageal cancer	0.000307	0.000644	CcSEcCtD
Mirtazapine—Dizziness—Methotrexate—esophageal cancer	0.000297	0.000622	CcSEcCtD
Mirtazapine—Vomiting—Methotrexate—esophageal cancer	0.000286	0.000598	CcSEcCtD
Mirtazapine—Rash—Methotrexate—esophageal cancer	0.000283	0.000593	CcSEcCtD
Mirtazapine—Dermatitis—Methotrexate—esophageal cancer	0.000283	0.000593	CcSEcCtD
Mirtazapine—Headache—Methotrexate—esophageal cancer	0.000281	0.000589	CcSEcCtD
Mirtazapine—Nausea—Methotrexate—esophageal cancer	0.000267	0.000559	CcSEcCtD
Mirtazapine—DRD3—GPCR downstream signaling—PIK3CA—esophageal cancer	2.38e-05	6.26e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—CRABP1—esophageal cancer	2.38e-05	6.25e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—HIF1A—esophageal cancer	2.37e-05	6.24e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—NOTCH1—esophageal cancer	2.35e-05	6.2e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—HIF1A—esophageal cancer	2.33e-05	6.14e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—HIF1A—esophageal cancer	2.33e-05	6.13e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling by GPCR—PIK3CA—esophageal cancer	2.32e-05	6.11e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	2.31e-05	6.07e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—CREBBP—esophageal cancer	2.31e-05	6.07e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—CYP19A1—esophageal cancer	2.29e-05	6.02e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Metabolism—NOS3—esophageal cancer	2.29e-05	6.02e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—HIF1A—esophageal cancer	2.28e-05	6.01e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—ERBB2—esophageal cancer	2.28e-05	6e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—KDR—esophageal cancer	2.27e-05	5.97e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling by GPCR—EGFR—esophageal cancer	2.27e-05	5.96e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—NOS3—esophageal cancer	2.27e-05	5.96e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—GNG7—esophageal cancer	2.26e-05	5.95e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—CREBBP—esophageal cancer	2.26e-05	5.94e-05	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling Pathways—CCND1—esophageal cancer	2.24e-05	5.89e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—KDR—esophageal cancer	2.23e-05	5.87e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—KDR—esophageal cancer	2.23e-05	5.86e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling by GPCR—EGFR—esophageal cancer	2.22e-05	5.83e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—CREBBP—esophageal cancer	2.21e-05	5.81e-05	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—CCND1—esophageal cancer	2.2e-05	5.8e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—CREBBP—esophageal cancer	2.19e-05	5.78e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—KDR—esophageal cancer	2.18e-05	5.75e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling by GPCR—EGFR—esophageal cancer	2.17e-05	5.7e-05	CbGpPWpGaD
Mirtazapine—ADRB1—GPCR downstream signaling—PIK3CA—esophageal cancer	2.17e-05	5.7e-05	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling Pathways—CDKN1A—esophageal cancer	2.16e-05	5.7e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling by GPCR—PIK3CA—esophageal cancer	2.16e-05	5.68e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling by GPCR—EGFR—esophageal cancer	2.16e-05	5.68e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—NOTCH1—esophageal cancer	2.14e-05	5.62e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—CREBBP—esophageal cancer	2.13e-05	5.62e-05	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—CDKN1A—esophageal cancer	2.13e-05	5.61e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—HIF1A—esophageal cancer	2.12e-05	5.59e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—ERBB2—esophageal cancer	2.12e-05	5.58e-05	CbGpPWpGaD
Mirtazapine—ADRB2—GPCR downstream signaling—PIK3CA—esophageal cancer	2.12e-05	5.58e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—ALDH2—esophageal cancer	2.12e-05	5.57e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—CCND1—esophageal cancer	2.11e-05	5.55e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—HMOX1—esophageal cancer	2.11e-05	5.54e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.1e-05	5.54e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—NOTCH1—esophageal cancer	2.1e-05	5.53e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling by GPCR—EGFR—esophageal cancer	2.1e-05	5.52e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—NOTCH1—esophageal cancer	2.1e-05	5.52e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Metabolism—PTGS2—esophageal cancer	2.09e-05	5.5e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—HMOX1—esophageal cancer	2.09e-05	5.5e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—CYP1B1—esophageal cancer	2.08e-05	5.47e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Metabolism—CREBBP—esophageal cancer	2.07e-05	5.46e-05	CbGpPWpGaD
Mirtazapine—HTR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	2.07e-05	5.45e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—NOS3—esophageal cancer	2.06e-05	5.43e-05	CbGpPWpGaD
Mirtazapine—HTR2C—GPCR downstream signaling—PIK3CA—esophageal cancer	2.06e-05	5.42e-05	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling Pathways—EP300—esophageal cancer	2.06e-05	5.42e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—NOTCH1—esophageal cancer	2.06e-05	5.42e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.05e-05	5.39e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—CDKN1A—esophageal cancer	2.04e-05	5.37e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—KDR—esophageal cancer	2.03e-05	5.34e-05	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—EP300—esophageal cancer	2.03e-05	5.34e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—ABCB1—esophageal cancer	2.02e-05	5.32e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—NOS3—esophageal cancer	2.02e-05	5.32e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—GSTT1—esophageal cancer	2.01e-05	5.3e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—CCND1—esophageal cancer	2.01e-05	5.3e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—GPCR downstream signaling—PIK3CA—esophageal cancer	2e-05	5.28e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—ABCB1—esophageal cancer	2e-05	5.27e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.99e-05	5.24e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—NOS3—esophageal cancer	1.97e-05	5.2e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling by GPCR—PIK3CA—esophageal cancer	1.97e-05	5.18e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—NOS3—esophageal cancer	1.96e-05	5.17e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—CYP19A1—esophageal cancer	1.95e-05	5.15e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—CDKN1A—esophageal cancer	1.95e-05	5.12e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—EP300—esophageal cancer	1.94e-05	5.11e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—CREBBP—esophageal cancer	1.94e-05	5.1e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—ERBB2—esophageal cancer	1.93e-05	5.08e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling by GPCR—PIK3CA—esophageal cancer	1.92e-05	5.06e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—NOTCH1—esophageal cancer	1.91e-05	5.03e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—NOS3—esophageal cancer	1.91e-05	5.03e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	1.91e-05	5.02e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling by GPCR—EGFR—esophageal cancer	1.9e-05	5.01e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—CREBBP—esophageal cancer	1.9e-05	5e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—ERBB2—esophageal cancer	1.89e-05	4.97e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.89e-05	4.97e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—ENO1—esophageal cancer	1.89e-05	4.97e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	1.88e-05	4.95e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—CCND1—esophageal cancer	1.87e-05	4.93e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	1.87e-05	4.93e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	1.87e-05	4.93e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling by GPCR—EGFR—esophageal cancer	1.87e-05	4.92e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—CREBBP—esophageal cancer	1.87e-05	4.91e-05	CbGpPWpGaD
Mirtazapine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.86e-05	4.9e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—PSME2—esophageal cancer	1.86e-05	4.9e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—PSME1—esophageal cancer	1.86e-05	4.9e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Metabolism—NOS3—esophageal cancer	1.86e-05	4.89e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—EP300—esophageal cancer	1.85e-05	4.88e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	1.85e-05	4.86e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	1.84e-05	4.84e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling by GPCR—EGFR—esophageal cancer	1.83e-05	4.83e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling by GPCR—PIK3CA—esophageal cancer	1.82e-05	4.79e-05	CbGpPWpGaD
Mirtazapine—DRD2—GPCR downstream signaling—PIK3CA—esophageal cancer	1.82e-05	4.79e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—CDKN1A—esophageal cancer	1.81e-05	4.77e-05	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling Pathways—MYC—esophageal cancer	1.79e-05	4.72e-05	CbGpPWpGaD
Mirtazapine—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.79e-05	4.71e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—ERBB2—esophageal cancer	1.79e-05	4.7e-05	CbGpPWpGaD
Mirtazapine—HRH1—GPCR downstream signaling—PIK3CA—esophageal cancer	1.79e-05	4.7e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—HMOX1—esophageal cancer	1.78e-05	4.7e-05	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—MYC—esophageal cancer	1.77e-05	4.65e-05	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling Pathways—EGFR—esophageal cancer	1.75e-05	4.62e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.75e-05	4.61e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.75e-05	4.61e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Metabolism—EP300—esophageal cancer	1.74e-05	4.58e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—NOS3—esophageal cancer	1.73e-05	4.56e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—CREBBP—esophageal cancer	1.73e-05	4.56e-05	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—EGFR—esophageal cancer	1.73e-05	4.55e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—EP300—esophageal cancer	1.72e-05	4.54e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—ABCB1—esophageal cancer	1.71e-05	4.51e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—CCND1—esophageal cancer	1.71e-05	4.49e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—NOS3—esophageal cancer	1.71e-05	4.49e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling by GPCR—EGFR—esophageal cancer	1.7e-05	4.48e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—NOS3—esophageal cancer	1.7e-05	4.48e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Metabolism—PTGS2—esophageal cancer	1.7e-05	4.47e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—MYC—esophageal cancer	1.69e-05	4.45e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—NOS3—esophageal cancer	1.67e-05	4.4e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—CCND1—esophageal cancer	1.67e-05	4.39e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—EGFR—esophageal cancer	1.65e-05	4.35e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling by GPCR—PIK3CA—esophageal cancer	1.65e-05	4.35e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—CDKN1A—esophageal cancer	1.65e-05	4.34e-05	CbGpPWpGaD
Mirtazapine—CYP2C8—Metabolism—CREBBP—esophageal cancer	1.65e-05	4.33e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—CCND1—esophageal cancer	1.63e-05	4.3e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.63e-05	4.29e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	1.62e-05	4.28e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—CCND1—esophageal cancer	1.62e-05	4.27e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—ERBB2—esophageal cancer	1.62e-05	4.27e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling by GPCR—PIK3CA—esophageal cancer	1.62e-05	4.27e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—CDKN1A—esophageal cancer	1.61e-05	4.25e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—MYC—esophageal cancer	1.61e-05	4.25e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.6e-05	4.22e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	1.6e-05	4.2e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—ERBB2—esophageal cancer	1.59e-05	4.19e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling by GPCR—PIK3CA—esophageal cancer	1.59e-05	4.19e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—CCND1—esophageal cancer	1.58e-05	4.16e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—EGFR—esophageal cancer	1.58e-05	4.16e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	1.58e-05	4.16e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	1.57e-05	4.13e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—EP300—esophageal cancer	1.57e-05	4.13e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—ERBB2—esophageal cancer	1.56e-05	4.11e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—NOS3—esophageal cancer	1.55e-05	4.09e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—EP300—esophageal cancer	1.54e-05	4.04e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—CDKN1A—esophageal cancer	1.53e-05	4.02e-05	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling Pathways—PIK3CA—esophageal cancer	1.52e-05	4.01e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.51e-05	3.99e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.51e-05	3.97e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—EP300—esophageal cancer	1.5e-05	3.95e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—MYC—esophageal cancer	1.5e-05	3.95e-05	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—PIK3CA—esophageal cancer	1.5e-05	3.95e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—EP300—esophageal cancer	1.49e-05	3.93e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling by GPCR—PIK3CA—esophageal cancer	1.48e-05	3.89e-05	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling Pathways—TP53—esophageal cancer	1.47e-05	3.88e-05	CbGpPWpGaD
Mirtazapine—CYP2C8—Metabolism—NOS3—esophageal cancer	1.47e-05	3.88e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—EGFR—esophageal cancer	1.47e-05	3.87e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—EP300—esophageal cancer	1.45e-05	3.83e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—ERBB2—esophageal cancer	1.45e-05	3.82e-05	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—TP53—esophageal cancer	1.45e-05	3.82e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—PIK3CA—esophageal cancer	1.44e-05	3.78e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—CCND1—esophageal cancer	1.43e-05	3.77e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Metabolism—EP300—esophageal cancer	1.41e-05	3.72e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—CCND1—esophageal cancer	1.41e-05	3.71e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—CCND1—esophageal cancer	1.41e-05	3.7e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—TP53—esophageal cancer	1.39e-05	3.66e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—CDKN1A—esophageal cancer	1.39e-05	3.65e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—CCND1—esophageal cancer	1.38e-05	3.63e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.38e-05	3.62e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—PIK3CA—esophageal cancer	1.37e-05	3.61e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—MYC—esophageal cancer	1.37e-05	3.6e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	1.36e-05	3.59e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—CDKN1A—esophageal cancer	1.36e-05	3.58e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—CREBBP—esophageal cancer	1.35e-05	3.56e-05	CbGpPWpGaD
Mirtazapine—CYP2C8—Metabolism—PTGS2—esophageal cancer	1.35e-05	3.55e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—CREBBP—esophageal cancer	1.34e-05	3.53e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—MYC—esophageal cancer	1.34e-05	3.52e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—EGFR—esophageal cancer	1.34e-05	3.52e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—CDKN1A—esophageal cancer	1.34e-05	3.51e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—TP53—esophageal cancer	1.33e-05	3.49e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.32e-05	3.48e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—EP300—esophageal cancer	1.32e-05	3.47e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—EGFR—esophageal cancer	1.31e-05	3.45e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—MYC—esophageal cancer	1.31e-05	3.45e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—MYC—esophageal cancer	1.3e-05	3.43e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—EP300—esophageal cancer	1.3e-05	3.42e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—EP300—esophageal cancer	1.29e-05	3.41e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.29e-05	3.41e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Metabolism—PIK3CA—esophageal cancer	1.29e-05	3.38e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—CCND1—esophageal cancer	1.28e-05	3.38e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—EGFR—esophageal cancer	1.28e-05	3.37e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—PIK3CA—esophageal cancer	1.27e-05	3.36e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—EGFR—esophageal cancer	1.27e-05	3.35e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—EP300—esophageal cancer	1.27e-05	3.34e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—MYC—esophageal cancer	1.27e-05	3.33e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—CDKN1A—esophageal cancer	1.24e-05	3.27e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—EGFR—esophageal cancer	1.24e-05	3.26e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—TP53—esophageal cancer	1.23e-05	3.25e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—NOS3—esophageal cancer	1.21e-05	3.18e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—NOS3—esophageal cancer	1.2e-05	3.16e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—EP300—esophageal cancer	1.18e-05	3.11e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—PIK3CA—esophageal cancer	1.16e-05	3.06e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—MYC—esophageal cancer	1.15e-05	3.03e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—CREBBP—esophageal cancer	1.14e-05	3.01e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—PIK3CA—esophageal cancer	1.14e-05	2.99e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—MYC—esophageal cancer	1.13e-05	2.98e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—MYC—esophageal cancer	1.13e-05	2.97e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—EGFR—esophageal cancer	1.12e-05	2.96e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—TP53—esophageal cancer	1.12e-05	2.96e-05	CbGpPWpGaD
Mirtazapine—CYP2C8—Metabolism—EP300—esophageal cancer	1.12e-05	2.95e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	1.11e-05	2.92e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—MYC—esophageal cancer	1.11e-05	2.91e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—PTGS2—esophageal cancer	1.11e-05	2.91e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—EGFR—esophageal cancer	1.11e-05	2.91e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	1.11e-05	2.91e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—EGFR—esophageal cancer	1.1e-05	2.91e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—TP53—esophageal cancer	1.1e-05	2.89e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—PTGS2—esophageal cancer	1.1e-05	2.89e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—EGFR—esophageal cancer	1.08e-05	2.85e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—PIK3CA—esophageal cancer	1.08e-05	2.83e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—TP53—esophageal cancer	1.07e-05	2.83e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—TP53—esophageal cancer	1.07e-05	2.81e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Metabolism—PIK3CA—esophageal cancer	1.04e-05	2.75e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—TP53—esophageal cancer	1.04e-05	2.74e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—MYC—esophageal cancer	1.03e-05	2.71e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—NOS3—esophageal cancer	1.02e-05	2.7e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—EGFR—esophageal cancer	1.01e-05	2.65e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—PIK3CA—esophageal cancer	9.76e-06	2.57e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	9.6e-06	2.53e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—PIK3CA—esophageal cancer	9.58e-06	2.52e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—TP53—esophageal cancer	9.44e-06	2.48e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—PIK3CA—esophageal cancer	9.4e-06	2.47e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—PTGS2—esophageal cancer	9.37e-06	2.47e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—TP53—esophageal cancer	9.29e-06	2.44e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—TP53—esophageal cancer	9.27e-06	2.44e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—EP300—esophageal cancer	9.2e-06	2.42e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—EP300—esophageal cancer	9.12e-06	2.4e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—TP53—esophageal cancer	9.09e-06	2.39e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—CREBBP—esophageal cancer	8.83e-06	2.32e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—PIK3CA—esophageal cancer	8.73e-06	2.3e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—TP53—esophageal cancer	8.45e-06	2.22e-05	CbGpPWpGaD
Mirtazapine—CYP2C8—Metabolism—PIK3CA—esophageal cancer	8.29e-06	2.18e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—NOS3—esophageal cancer	7.91e-06	2.08e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—EP300—esophageal cancer	7.79e-06	2.05e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—PTGS2—esophageal cancer	7.23e-06	1.9e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	6.81e-06	1.79e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—PIK3CA—esophageal cancer	6.75e-06	1.78e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—EP300—esophageal cancer	6.02e-06	1.58e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—PIK3CA—esophageal cancer	5.77e-06	1.52e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	4.45e-06	1.17e-05	CbGpPWpGaD
